{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-038536","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.491623+00:00","generated_at":"2026-06-24T17:47:16.166654+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity appoints three new directors, expands board from 4 to 6 members","bullets":["Board size increased to 6; new directors: David Roth (independent), James Cullem (Interim CEO), Thomas Jensen (co-founder, SVP IR).","David Roth, M.D., brings 25+ years oncology drug development experience; currently CMO of Syros Pharmaceuticals.","Bylaws amended: stockholder quorum reduced from majority to 33.33% of voting power.","Independent director annual retainer raised to $50,000; Roth received options for 23,000 shares at $1.28.","Cullem continues as CEO and Chief Business Officer; Jensen as SVP Investor Relations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-038536","json":"https://secwatch.observer/filing/0001213900-22-038536.json","markdown":"https://secwatch.observer/filing/0001213900-22-038536.md","text":"https://secwatch.observer/filing/0001213900-22-038536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/ea162649-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:47:16.166654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"701419a780","claim":"James G. Cullem was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"962529b2b6","claim":"David Roth was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d59cceb615","claim":"Thomas Jensen was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}